Last reviewed · How we verify

Cimicifuga + Hiperico

Phytopharm Consulting Brazil · Phase 3 active Small molecule

This herbal combination product uses Cimicifuga (black cohosh) and Hypericum (St. John's Wort) to modulate serotonergic and hormonal pathways, potentially alleviating menopausal symptoms and mood disturbances.

This herbal combination product uses Cimicifuga (black cohosh) and Hypericum (St. John's Wort) to modulate serotonergic and hormonal pathways, potentially alleviating menopausal symptoms and mood disturbances. Used for Menopausal symptoms (hot flashes, night sweats, mood disturbances).

At a glance

Generic nameCimicifuga + Hiperico
SponsorPhytopharm Consulting Brazil
Drug classHerbal combination / phytotherapeutic agent
ModalitySmall molecule
Therapeutic areaWomen's Health / Menopause
PhasePhase 3

Mechanism of action

Cimicifuga contains triterpene glycosides and other phytochemicals that may act on serotonin receptors and estrogen pathways to reduce hot flashes and night sweats. Hypericum perforatum (St. John's Wort) is a known monoamine oxidase inhibitor and serotonin reuptake modulator that may improve mood and anxiety associated with menopause. The combination targets both vasomotor and psychological symptoms of the menopausal transition.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: